Form 4: Edgewise CSO's Stock Transactions & New Grants
Insider Transaction Report
Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported routine stock transactions including RSU vesting, a sell-to-cover tax sale, and new equity grants.
Summary
- Chief Scientific Officer Alan J. Russell reported changes in his beneficial ownership of Edgewise Therapeutics, Inc. common stock and derivative securities.
- On August 12, 2025, 5,781 Restricted Stock Units (RSUs) vested, converting into common stock.
- Concurrently, 1,907 shares of common stock were sold at an average price of $13.3924 to cover statutory tax withholding obligations related to the RSU vesting. This was a non-discretionary 'sell-to-cover' transaction.
- Russell was granted 28,125 new Restricted Stock Units (RSUs) on August 12, 2025, which will vest in four equal annual installments starting August 12, 2026.
- Additionally, 168,750 stock options were granted on August 12, 2025, with an exercise price of $13.39. These options will vest monthly over 48 months, beginning September 12, 2025.
- Following these transactions, Russell directly beneficially owns 23,400 shares of common stock, 45,469 Restricted Stock Units, and 168,750 stock options.
Sentiment
Score: 6
Explanation: The filing indicates routine equity compensation activities for a key executive, including RSU vesting, a non-discretionary tax-related sale, and new grants of RSUs and stock options. This is generally neutral, but the new grants are a positive sign of continued executive alignment and retention, slightly tipping the sentiment to positive.
Positives
- Grant of 28,125 new Restricted Stock Units (RSUs) to the Chief Scientific Officer, indicating continued long-term incentive alignment.
- Grant of 168,750 stock options to the Chief Scientific Officer, further aligning management's interests with shareholder value creation.
Negatives
- Sale of 1,907 shares of common stock, although noted as a non-discretionary 'sell-to-cover' for tax obligations.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The new equity grants align the Chief Scientific Officer's interests with long-term shareholder value. The sell-to-cover is a routine, non-discretionary event.
- Employees: The mention of the Employee Stock Purchase Plan indicates a broader employee benefit program.
Next Steps
- Monthly vesting of 168,750 stock options beginning September 12, 2025.
- Annual vesting installments for 28,125 RSUs beginning August 12, 2026.
Key Dates
| Date | Description |
|---|---|
| 2021 | Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan established. |
| 05/15/2025 | 1,005 shares purchased pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| 08/12/2025 | Date of RSU vesting, common stock acquisition, common stock disposition (sell-to-cover), new RSU grant, and new stock option grant. |
| 08/12/2025 | First vesting installment for 5,781 RSUs begins. |
| 09/12/2025 | Monthly vesting for 168,750 stock options begins. |
| 08/12/2026 | First vesting installment for 28,125 new RSUs begins. |
| 08/12/2034 | Expiration date for the contingent right to receive shares from the 5,781 RSUs. |
| 08/12/2035 | Expiration date for 28,125 new RSUs. |
| 08/12/2035 | Expiration date for 168,750 stock options. |
| 08/14/2025 | Date of filing signature. |
Keywords
Edgewise Therapeutics, EWTX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Alan J. Russell, Chief Scientific Officer, Stock Sale, Stock Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.